MutExSL

MutExSL identifies synthetic‑lethal candidate gene pairs by analyzing mutually exclusive copy‑number and gene‑expression alterations in TCGA breast, prostate, ovarian, and uterine cancer samples (3980 samples) to prioritize targets related to DNA‑damage response (DDR).

Key Features:

• Data Utilization: MutExSL leverages genomic copy‑number and gene‑expression data from The Cancer Genome Atlas (TCGA) for breast, prostate, ovarian, and uterine cancers across 3980 samples.
• Identification of Frequently Altered Genes: The tool identifies genes that are frequently amplified or upregulated in these cancer types and prioritizes potential interactions with DNA‑damage response (DDR) genes.
• Mutual Exclusivity Analysis: MutExSL infers likely lethal combinations by detecting gene pairs altered in a significantly mutually exclusive manner, based on the premise that mutual exclusivity reflects functional redundancy or compensatory pathways.
• Enrichment with Essential Genes: Identified genes are cross‑referenced with published gene essentiality data from ten DDR‑deficient cancer cell lines (~16,000 genes) and are enriched among the top quartile of essential genes in those cell lines.
• Potential Therapeutic Targets: The analysis nominates targets including TLK2 and USP7, both associated with poor survival when overexpressed in cancers.

Scientific Applications:

• Cancer Research: Identification of synthetic‑lethal interactions specific to human cancers to inform studies of genetic vulnerabilities.
• Therapeutic Development: Prioritization of novel therapeutic targets by pinpointing genes essential for cancer cell survival when DDR pathways are compromised.
• Precision Medicine: Support for precision medicine approaches by focusing on frequently altered and mutually exclusive gene pairs tied to tumor genetic profiles.

Methodology:

Uses TCGA copy‑number and gene‑expression data from breast, prostate, ovarian, and uterine cancers (3980 samples); identifies frequently amplified or upregulated genes; detects significantly mutually exclusive gene pairs to infer synthetic‑lethal combinations; and cross‑references results with published essentiality data from ten DDR‑deficient cancer cell lines (~16,000 genes).